Reprogram Biosciences, a biotech startup pioneering a new strategy to fight cancer by converting harmful cells into beneficial immune cells, has closed a $6.0M seed funding round.
The capital infusion will advance its unique cell reprogramming technology, which aims to directly transform disease-causing cells inside the body. This innovative approach promises not only safer and more accessible cancer treatments but also holds significant potential to revolutionize therapies for a wide array of other diseases, simplifying effective solutions for patients.
